La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Getein Biotech Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	3.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Getein Biotech non ha un CEO, o non abbiamo dati su di loro.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Gang Zhu	Deputy GM & Director	3.8yrs	CN¥904.60k	Nessun dato
Xingde Zhuo	Director	no data	Nessun dato	Nessun dato
Honghai Yu	Independent Director	3.8yrs	CN¥100.00k	Nessun dato
Suiren Wan	Independent Director	3.8yrs	CN¥100.00k	Nessun dato
Jing Luo	Independent Director	2yrs	CN¥25.00k	Nessun dato
Jun Chen	Independent Director	3.8yrs	Nessun dato	Nessun dato
Jing Li	Chairman of the Supervisory Board	9.8yrs	CN¥100.00k	Nessun dato
Wu Zhang	Supervisor	3.8yrs	Nessun dato	Nessun dato

3.8yrs

Durata media

46yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 603387 sono considerati esperti (durata media dell'incarico 3.7 anni).

Getein Biotech Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Getein Biotech, Inc, Annual General Meeting, May 22, 2024

High number of new and inexperienced directors

Recent updates

Investor sentiment improves as stock rises 15%

First half dividend reduced to CN¥0.09

Now 20% overvalued

Getein Biotech, Inc to Report First Half, 2024 Results on Aug 29, 2024

Dividend of CN¥0.10 announced

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.98 in FY 2022)

Getein Biotech, Inc, Annual General Meeting, May 22, 2024

Getein Biotech, Inc to Report Q1, 2024 Results on Apr 27, 2024

Investor sentiment deteriorates as stock falls 17%

Getein Biotech, Inc to Report Fiscal Year 2023 Results on Apr 27, 2024

Third quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.28 in 3Q 2022)

High number of new and inexperienced directors

Now 20% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: CN¥0.091 (vs CN¥0.22 in 2Q 2022)

Getein Biotech, Inc to Report First Half, 2023 Results on Aug 29, 2023

Now 21% undervalued

Full year 2022 earnings released: EPS: CN¥0.97 (vs CN¥0.79 in FY 2021)

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.16 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 2Q 2021)

Full year 2021 earnings released: EPS: CN¥1.10 (vs CN¥0.84 in FY 2020)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.27 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.24 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.12 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.20 (vs CN¥1.31 in FY 2019)

New 90-day low: CN¥30.30

New 90-day low: CN¥30.80

New 90-day low: CN¥31.42

New 90-day low: CN¥34.80

Third quarter earnings released

New 90-day high: CN¥41.89

First half earnings released

Getein Biotech, Inc (SHSE:603387) completed the acquisition of 54.96% stake in Wuhan King Diagnostic Technology Co.,Ltd. from a group of 21 sellers.

Getein Biotech, Inc to Report First Half, 2020 Results on Aug 27, 2020

AMMINISTRATORE DELEGATO

Membri del Consiglio di amministrazione

Durata media

Età media